JP2020525005A - 抗ｖｉｓｔａ抗体および使用方法 - Google Patents

抗ｖｉｓｔａ抗体および使用方法 Download PDF

Info

Publication number
JP2020525005A
JP2020525005A JP2019570807A JP2019570807A JP2020525005A JP 2020525005 A JP2020525005 A JP 2020525005A JP 2019570807 A JP2019570807 A JP 2019570807A JP 2019570807 A JP2019570807 A JP 2019570807A JP 2020525005 A JP2020525005 A JP 2020525005A
Authority
JP
Japan
Prior art keywords
antigen
antibody
binding fragment
cancer
vista
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019570807A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020525005A5 (https=
Inventor
エリン エル． フィルバート，
エリン エル． フィルバート，
クリスティン タン，
クリスティン タン，
ピア ビョルク，
ピア ビョルク，
シャオドン ヤン，
シャオドン ヤン，
Original Assignee
アペクシジェン， インコーポレイテッド
アペクシジェン， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アペクシジェン， インコーポレイテッド, アペクシジェン， インコーポレイテッド filed Critical アペクシジェン， インコーポレイテッド
Publication of JP2020525005A publication Critical patent/JP2020525005A/ja
Publication of JP2020525005A5 publication Critical patent/JP2020525005A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019570807A 2017-06-22 2018-06-22 抗ｖｉｓｔａ抗体および使用方法 Pending JP2020525005A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762523649P 2017-06-22 2017-06-22
US62/523,649 2017-06-22
PCT/US2018/039036 WO2018237287A1 (en) 2017-06-22 2018-06-22 Anti-vista antibodies and methods of use

Publications (2)

Publication Number Publication Date
JP2020525005A true JP2020525005A (ja) 2020-08-27
JP2020525005A5 JP2020525005A5 (https=) 2021-07-26

Family

ID=64737864

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019570807A Pending JP2020525005A (ja) 2017-06-22 2018-06-22 抗ｖｉｓｔａ抗体および使用方法

Country Status (6)

Country Link
US (1) US20210139589A1 (https=)
EP (1) EP3642231A4 (https=)
JP (1) JP2020525005A (https=)
CN (1) CN110959013A (https=)
CA (1) CA3067835A1 (https=)
WO (1) WO2018237287A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3568159A4 (en) 2017-01-11 2020-08-05 Bristol-Myers Squibb Company PSGL-1 ANTAGONISTS AND THEIR USES
KR102715540B1 (ko) 2017-03-14 2024-10-08 파이브 프라임 테라퓨틱스, 인크. 산성 pH에서 VISTA에 결합하는 항체
BR112020019083A2 (pt) 2018-03-21 2020-12-29 Five Prime Therapeutics, Inc. Anticorpos, ácido nucleico, composições, célula e métodos para preparar um anticorpo, para tratar câncer, para tratar uma doença infecciosa, para tratar uma inflamação, para a identificação de um anticorpo, para melhorar a eficácia antitumoral de um anticorpo, para melhorar a farmacocinética de um anticorpo, para selecionar um anticorpo, para melhorar a eficácia de anticorpos, para isolar anticorpos, para detectar vista em uma amostra e para tratar câncer
BR112021000303A2 (pt) 2018-07-11 2021-04-13 Five Prime Therapeutics, Inc. Anticorpos que se ligam a vista em ph ácido
US10577424B1 (en) * 2019-08-15 2020-03-03 Beijing Mabworks Biotech Co., Ltd. Antibodies binding VISTA and uses thereof
US20230130372A1 (en) * 2019-12-17 2023-04-27 The Board Of Regents Of The University Of Texas System Novel ddr1 antibodies and uses thereof
EP4199947A4 (en) 2020-08-18 2024-10-16 Onchilles Pharma, Inc. Modified porcine pancreatic elastase proteins
US12551584B1 (en) * 2020-12-07 2026-02-17 Actinium Pharmaceuticals, Inc. Lewis Y radioimmunotherapy for the treatment of cancer
WO2025026168A1 (zh) * 2023-07-28 2025-02-06 北京亦庄国际蛋白药物技术有限公司 抗vista的抗体或其抗原结合片段及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015533796A (ja) * 2012-09-07 2015-11-26 トラスティーズ・オブ・ダートマス・カレッジ 癌の診断および治療のためのｖｉｓｔａ調節剤
WO2016094837A2 (en) * 2014-12-11 2016-06-16 Igenica Biotherapeutics, Inc. Anti-c10orf54 antibodies and uses thereof
JP2017502667A (ja) * 2013-12-24 2017-01-26 ヤンセン ファーマシューティカ エヌブイ 抗ｖｉｓｔａ抗体および断片

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005023617A1 (de) * 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
NZ563370A (en) * 2005-06-20 2010-10-29 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
US8404235B2 (en) * 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
CN102781963B (zh) * 2009-10-27 2018-02-16 Ucb医药有限公司 功能修饰性NAv1.7抗体
US20150231215A1 (en) * 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
JP6190723B2 (ja) * 2010-12-01 2017-08-30 アルダーバイオ ホールディングス エルエルシー 抗ｎｇｆ組成物およびその使用
KR20140043724A (ko) * 2011-03-03 2014-04-10 아펙시젠, 인코포레이티드 항-il-6 수용체 항체 및 사용 방법
US9441042B2 (en) * 2011-11-02 2016-09-13 Apexigen, Inc. Anti-KDR antibodies and methods of use
US9255154B2 (en) * 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
US9890215B2 (en) * 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
DK3421486T5 (da) * 2012-06-22 2024-09-16 The Trustees Of Darthmouth College Nye Vista-IG-konstruktioner og anvendelse af Vista-IG til behandling af autoimmune, allergiske og inflammatoriske lidelser
GB201223276D0 (en) * 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
MX2015016978A (es) * 2013-06-10 2016-04-25 Merck Sharp & Dohme Proteinas de union a antigeno neutralizantes de citomegalovirus.
JP2018505911A (ja) * 2014-12-05 2018-03-01 イミュネクスト，インコーポレーテッド 推定上のｖｉｓｔａ受容体としてのｖｓｉｇ８の同定と、ｖｉｓｔａ／ｖｓｉｇ８調節剤を産生するためのその使用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015533796A (ja) * 2012-09-07 2015-11-26 トラスティーズ・オブ・ダートマス・カレッジ 癌の診断および治療のためのｖｉｓｔａ調節剤
JP2017502667A (ja) * 2013-12-24 2017-01-26 ヤンセン ファーマシューティカ エヌブイ 抗ｖｉｓｔａ抗体および断片
WO2016094837A2 (en) * 2014-12-11 2016-06-16 Igenica Biotherapeutics, Inc. Anti-c10orf54 antibodies and uses thereof

Also Published As

Publication number Publication date
CN110959013A (zh) 2020-04-03
EP3642231A1 (en) 2020-04-29
WO2018237287A1 (en) 2018-12-27
EP3642231A4 (en) 2021-06-23
US20210139589A1 (en) 2021-05-13
CA3067835A1 (en) 2018-12-27

Similar Documents

Publication Publication Date Title
TWI854026B (zh) 抗ｔｎｆｒ２抗體及使用方法
JP7482184B2 (ja) 抗ｃｄ４０抗体および使用方法
JP6807890B2 (ja) 抗ｃｄ４０抗体および使用方法
JP2020525005A (ja) 抗ｖｉｓｔａ抗体および使用方法
JP2014515612A5 (https=)
US20230340112A1 (en) Anti-sirpa antibodies and methods of use
US20210139594A1 (en) Anti-cd40 antibodies in combination and methods of use
EA050555B1 (ru) Антитела к tnfr2 и способы применения
JP2020514273A (ja) 白斑症の処置のための抗ヒトｃｘｃｒ３抗体
HK40025350A (en) Anti-vista antibodies and methods of use
HK40011413A (en) Anti-cd40 antibodies and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210611

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210611

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220427

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221116